Biocon Biologics Expands Collaboration with Civica to Provide Affordable Insulin Glargine in the US

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced an expansion of its partnership with Civica, Inc. This collaboration now includes a new Insulin Glargine product, aimed at enhancing the availability of affordable, high-quality insulins for patients in the United States. Under this multi-year agreement, BBL will produce and supply Insulin Glargine to Civica for commercialisation.

Representative image

Civica will handle the distribution, promotion, and sales of the insulin in the US under its own branding. In California, it will be marketed as CalRx. Meanwhile, BBL will continue to directly market its Insulin Glargine-yfgn, which received approval from the US Food and Drug Administration (FDA) in July 2021 as the first interchangeable biosimilar insulin.

Strategic Collaboration with Civica

The agreement allows Civica to sell the product under BBL’s existing marketing approval through a private-label arrangement. Shreehas Tambe, CEO and Managing Director of Biocon Biologics Ltd, stated, "Biocon Biologics is committed to expanding access to affordable, high-quality insulins in the US and globally."

Tambe further explained that by extending their collaboration with Civica to include Insulin Glargine, they are enhancing patient access through both direct commercialisation and strategic partnerships. This approach aims to serve patients better by ensuring they have access to necessary medications.

This partnership reflects BBL's dedication to providing accessible healthcare solutions. By working with Civica, they aim to address the growing demand for affordable insulin options in the United States. The collaboration is expected to benefit many patients who rely on insulin for managing their health conditions.

BBL's ongoing efforts to make high-quality insulins more accessible align with their broader mission of improving global healthcare. The company continues to explore innovative ways to meet patient needs while maintaining high standards of quality and affordability in their products.

With inputs from PTI